U266B1, or U266/U-266 (ATCC® TIB-196™)*, cells are a plasma cell myeloma (multiple myeloma) cell line originally isolated from the peripheral blood of a 53-year old male.1 The cells are negative for EBV.2
U266B1 cells are highly characterized. They are part of the MD Anderson Cell Lines Project and the LL-100 blood cancer cell line panel.3,4 The cells express plasma cell-associated antigens (PCA-1, CD38, CD56, CD44, syndecan-1) and BCMA, but not the B-lymphocyte antigens CD19 or CD20.5,6 The cells secrete IgE1 and can be used as a fusion partner in human hybridomas for production of human monoclonal antibodies.7 U266B1 cells express IL-6 and are not dependent on exogenous IL-6 for growth.8
U266B1 cells are tumorigenic in vivo in immunocompromised mice. When implanted via the tail vein, the cells selectively grow within the bone marrow compartment.9 The cells can also be implanted as subcutaneous xenografts.10
Our U266B1 reporter cell lines can be used for in vitro or in vivo research. The luciferase (Fluc) and emerald green fluorescence protein (EmGFP) reporters facilitate easy quantitation of cells for in vitro assays. Additionally, luciferase can be used for tracking tumor growth non-invasively in living animals through bioluminescence imaging. Our reporter cells are generated by lentiviral vector transduction, ensuring high, constitutive expression of the reporter proteins. The lentiviral vectors used for these transductions are self-inactivating (SIN) vectors in which the viral enhancer and promoter have been deleted. This increases the biosafety of the lentiviral vectors by preventing mobilization of replication competent viruses.11
References:
*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.
Don’t see what you need in our catalog? Our scientific team engineers cell lines, viral vectors, and assays and provides as much characterization data as you need to move forward with confidence.
